Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective

References

• Gudjonsson JE, Johnston A, Sigmundsdottir H, et al. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004;135:1-8
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schon MP. Psoriasis. Lancet 2015;386:983-94
   PubMed Web of Science ®Google Scholar
• Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open 2015;5:e006450
   PubMed Web of Science ®Google Scholar
• Khalid JM, Globe G, Fox KM, et al. Treatment and referral patterns for psoriasis in United Kingdom primary care: a retrospective cohort study. BMC Dermatol 2013;13:9
   PubMedGoogle Scholar
• Hazard E, Cherry SB, Lalla D, et al. Clinical and economic burden of psoriasis. Manag Care Interface 2006;19:20-6
   PubMedGoogle Scholar
• Jaleel T, Elmets C, Weinkle A, et al. Secukinumab (AIN-457) for the treatment of Psoriasis. Expert Rev Clin Pharmacol 2016;9:187-202
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol 2013;40:683-95
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol 2015;16:323-30
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 2014;371:326-38
   PubMed Web of Science ®Google Scholar
• Reszke R, Szepietowski JC. Secukinumab in the treatment of psoriasis: an update. Immunotherapy 2017;9:229-38
   PubMed Web of Science ®Google Scholar
• Review report on secukinumab: pharmaceuticals and medical devices agency. Japan: Pharmaceuticals and Medical Devices Agency; 2015. Available at: http://www.pmda.go.jp/files/000216877.pdf [Last accessed April 19, 2017]
   Google Scholar
• Zhang W, Islam N, Ma C, et al. Systematic review of cost-effectiveness analyses of treatments for psoriasis. Pharmacoeconomics 2015;33:327-40
   PubMed Web of Science ®Google Scholar
• Gutknecht M, Krensel M, Augustin M. Health economic analyses of psoriasis management: a systematic literature search. Arch Dermatol Res 2016;308:601-16
   PubMed Web of Science ®Google Scholar
• Igarashi A, Kuwabara H, Fahrbach K, et al. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan. J Dermatolog Treat 2013;24:351-5
   PubMed Web of Science ®Google Scholar
• Costa-Scharplatz M, Lang A, Gustavsson A, et al. Cost-effectiveness of secukinumab compared to ustekinumab in patients with psoriasis from a Swedish health care perspective. Value Health 2015;18:A422
   PubMed Web of Science ®Google Scholar
• D’Ausilio A, Aiello A, Daniel F, et al. A cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis In Italy. Value Health 2015;18:A424
   PubMed Web of Science ®Google Scholar
• Klimes J, Mollon P, Graham C, et al. Cost-effectiveness analysis of secukinumab compared to ustekinumab in the treatment of moderate to severe plaque psoriasis in the Czech Republic. Value Health 2015;18:A424
   PubMed Web of Science ®Google Scholar
• Lee A, Gregory V, Gu Q, et al. Cost-effectiveness of secukinumab compared to current treatments for the treatment of moderate to severe plaque psoriasis in Canada. Value in Health 2015;18:A182
   Web of Science ®Google Scholar
• Kamae I. Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan. Pharmacoeconomics 2010;28:831-8
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Mitchell BD, Boye KS, et al. The health technology assessment environment in mainland China, Japan, South Korea, and Taiwan—implications for the evaluation of diabetes mellitus therapies. Value Health 2014;3:108-16
   Google Scholar
• Imafuku S, Nakano A, Dakeshita H, et al. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan. J Dermatolog Treat 2018;29:24–31
   PubMed Web of Science ®Google Scholar
• Takahashi H, Satoh K, Takagi A, et al. Economic burden of psoriatic patients in Japan: analysis from a single outpatient clinic. J Dermatol 2017;44:1024–1026
   Web of Science ®Google Scholar
• Review report on ustekinumab. Japan: Pharmaceuticals and Medical Devices Agency; 2010. Available at: http://www.pmda.go.jp/files/000153747.pdf [Last accessed April 19, 2017]
   Google Scholar
• Review Report on Adalimumab. Japan: Pharmaceuticals and Medical Devices Agency; 2016. Available at: http://www.info.pmda.go.jp/downfiles/ph/GUI/112130_3999426G1024_2_12G.pdf [Last accessed April 19, 2017]
   Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1-233,i–iv
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015;73:27-36.e1
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018;32:1507-14
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab sustains good efficacy and favourable safety in moderate to severe psoriasis up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol 2017;177:1033–1042
   Google Scholar
• Hawe E, Vickers AD, Mallya UG, et al. Secukinumab 300mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress. Amsterdam, the Netherlands, October 2014
   Google Scholar
• Bissonnette R, Luger T, Thaci D, et al. Secukinumab demonstrates sustained high efficacy and a favorable safety profile in moderate to severe psoriasis patients through 4 years of treatment (extension of sculpture study). Poster presented at the 25th European Academy of Dermatology and Venereology Congress. Vienna, Austria, 2016
   Google Scholar
• Guide to Japan’s National Health Insurance (NHI) System. 2017. Available at: https://yosida.com/forms/nationalins.pdf [Last accessed March 22, 2017]
   Google Scholar
• Shiroiwa T, Fukuda T, Ikeda S, et al. Development of an official guideline for the economic evaluation of drugs/medical devices in Japan. Value Health 2017;20:372-8
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010;19:422-37
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Igarashi A, Fukuda T, et al. WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc 2013;11:22
   PubMedGoogle Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Mukhtar R, Choi J, Koo JY. Quality-of-life issues in psoriasis. Dermatol Clin 2004;22:389-95,viii
   PubMed Web of Science ®Google Scholar
• Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol 2015;90:9-20
   PubMed Web of Science ®Google Scholar
• Owczarczyk-Saczonek A, Nowicki R. [Psoriasis and comorbidity—literature review]. Wiad Lek 2014;67:512-19
   PubMedGoogle Scholar
• Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-92
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-50
   PubMed Web of Science ®Google Scholar
• Kimball AB, Guerin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011;25:157-63
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One 2012;7:e52935
   PubMed Web of Science ®Google Scholar
• Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013;149:1173-9
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015;73:400-9
   PubMed Web of Science ®Google Scholar
• Augustin M, McBride D, Gilloteau I, et al. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol 2018
   Web of Science ®Google Scholar
• Buchanan V, Sullivan W, Graham C, et al. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics 2018;36:867-78
   PubMed Web of Science ®Google Scholar
• Goeree R, Chiva-Razavi S, Gunda P, et al. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ 2018;21:163-73
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. NICE; 2013. Available at: https://www.nice.org.uk/process/pmg9/chapter/foreword [Last accessed June 23, 2017]
   Google Scholar
• Dental and Pharmaceutical Benefits Board (TLV). General guidelines for economic evaluations from the pharmaceutical benefits board. TLV; 2003. Available at: https://www.tlv.se/Upload/English/Guidelines-for-economic-evaluations-LFNAR-2003-2.pdf [Last accessed June 23, 2017]
   Google Scholar
• Mauskopf J, Samuel M, McBride D, et al. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. PharmacoEconomics 2014;32:395-409
   PubMed Web of Science ®Google Scholar
• Collins A, Hawe E, Vickers A, et al. Secukinumab 300 mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison. Aust J Dermatol 2015;56:27-8
   Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
   PubMed Web of Science ®Google Scholar
• Various information of medical fee. Ministry of Health, Labour and Welfare; 2017. Available at: http://www.iryohoken.go.jp/shinryohoshu [Last accessed June 21, 2017]
   Google Scholar
• Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76
   PubMed Web of Science ®Google Scholar